Annual report
2370.TEDINET S100UX6K
Period2023-10-01 → 2024-09-30
Filed2024-12-18
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 83
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥769m | 2023-10-01 → 2024-09-30 | Standalone | Net sales |
| Revenue | ¥662m | 2022-10-01 → 2023-09-30 | Standalone | Net sales |
| Revenue | ¥634m | 2021-10-01 → 2022-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥683m | 2020-10-01 → 2021-09-30d | Standalone | Net sales (5-year summary) |
| Revenue | ¥783m | 2019-10-01 → 2020-09-30d | Standalone | Net sales (5-year summary) |
| Operating income | −¥1.4bn | 2023-10-01 → 2024-09-30 | Standalone | Operating income |
| Operating income | −¥1.4bn | 2022-10-01 → 2023-09-30 | Standalone | Operating income |
| Ordinary income | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.4bn | 2022-10-01 → 2023-09-30 | Standalone | Ordinary income |
| Ordinary income | −¥1.3bn | 2021-10-01 → 2022-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥871m | 2020-10-01 → 2021-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥837m | 2019-10-01 → 2020-09-30d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Income before income taxes |
| Profit before tax | −¥1.4bn | 2022-10-01 → 2023-09-30 | Standalone | Income before income taxes |
| Net income | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Profit loss |
| Net income | −¥1.4bn | 2022-10-01 → 2023-09-30 | Standalone | Profit loss |
| Net income | −¥1.3bn | 2021-10-01 → 2022-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | −¥843m | 2020-10-01 → 2021-09-30d | Standalone | Net income loss (5-year summary) |
| Net income | −¥842m | 2019-10-01 → 2020-09-30d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥5.7bn | at 2024-09-30 | Standalone | Assets |
| Total assets | ¥5.6bn | at 2023-09-30 | Standalone | Assets |
| Total assets | ¥6.1bn | at 2022-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.4bn | at 2021-09-30d | Standalone | Total assets (5-year summary) |
| Total assets | ¥5.2bn | at 2020-09-30d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥509m | at 2024-09-30 | Standalone | Liabilities |
| Total liabilities | ¥590m | at 2023-09-30 | Standalone | Liabilities |
| Net assets / equity | ¥5.2bn | at 2024-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.0bn | at 2023-09-30 | Standalone | Net assets |
| Net assets / equity | ¥5.5bn | at 2022-09-30d | Standalone | Net assets |
| Net assets / equity | ¥4.9bn | at 2021-09-30d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.8bn | at 2020-09-30d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4.7bn | at 2024-09-30 | Standalone | Cash and deposits |
| Cash and deposits | ¥4.4bn | at 2023-09-30 | Standalone | Cash and deposits |
| Cash & equivalents | ¥4.7bn | at 2024-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.4bn | at 2023-09-30 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.5bn | at 2022-09-30d | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥4.1bn | at 2021-09-30d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.6bn | at 2020-09-30d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥1.3bn | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.3bn | 2022-10-01 → 2023-09-30 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.2bn | 2021-10-01 → 2022-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥975m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥633m | 2019-10-01 → 2020-09-30d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥65m | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | ¥3m | 2022-10-01 → 2023-09-30 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥20m | 2021-10-01 → 2022-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥344m | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥86m | 2019-10-01 → 2020-09-30d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2023-10-01 → 2024-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.2bn | 2022-10-01 → 2023-09-30 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.6bn | 2021-10-01 → 2022-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2020-10-01 → 2021-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.8bn | 2019-10-01 → 2020-09-30d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-5.04 | 2023-10-01 → 2024-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.65 | 2022-10-01 → 2023-09-30 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.33 | 2021-10-01 → 2022-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-4.88 | 2020-10-01 → 2021-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.19 | 2019-10-01 → 2020-09-30d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥19.62 | at 2024-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥21.64 | at 2023-09-30 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥26.03 | at 2022-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥27.31 | at 2021-09-30d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥29.6 | at 2020-09-30d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 91.1% | at 2024-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.2% | at 2023-09-30 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2022-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.8% | at 2021-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 90.7% | at 2020-09-30d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -25.0% | 2023-10-01 → 2024-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -27.3% | 2022-10-01 → 2023-09-30 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -24.1% | 2021-10-01 → 2022-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -17.5% | 2020-10-01 → 2021-09-30d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -23.0% | 2019-10-01 → 2020-09-30d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 264,515,306 | at 2024-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 232,160,757 | at 2023-09-30 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 211,730,423 | at 2022-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 178,750,423 | at 2021-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 160,830,423 | at 2020-09-30d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 112 | at 2024-09-30 | Standalone | Number of employees |
| Employees | 98 | at 2023-09-30 | Standalone | Number of employees |
| Employees | 96 | at 2022-09-30d | Standalone | Number of employees |
| Employees | 83 | at 2021-09-30d | Standalone | Number of employees |
| Employees | 78 | at 2020-09-30d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-10-01 → 2024-09-30 | ¥2m |
| Reconciling Itemsreconciling | depreciation | 2023-10-01 → 2024-09-30 | ¥18m |
| Reconciling Itemsreconciling | segment assets | at 2024-09-30 | ¥4.9bn |
| Reconciling Itemsreconciling | segment profit | 2023-10-01 → 2024-09-30 | −¥577m |
| Cellular And Tissue Based Product Businessreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥21m |
| Cellular And Tissue Based Product Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥36m |
| Cellular And Tissue Based Product Businessreportable segment | employees | at 2024-09-30 | 18 pure |
| Cellular And Tissue Based Product Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥245,000 |
| Cellular And Tissue Based Product Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥245,000 |
| Cellular And Tissue Based Product Businessreportable segment | segment assets | at 2024-09-30 | ¥116m |
| Cellular And Tissue Based Product Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | −¥435m |
| Contracted Cell Manufacturing Businessreportable segment | capex | 2023-10-01 → 2024-09-30 | ¥23m |
| Contracted Cell Manufacturing Businessreportable segment | depreciation | 2023-10-01 → 2024-09-30 | ¥61m |
| Contracted Cell Manufacturing Businessreportable segment | employees | at 2024-09-30 | 78 pure |
| Contracted Cell Manufacturing Businessreportable segment | revenue | 2023-10-01 → 2024-09-30 | ¥768m |
| Contracted Cell Manufacturing Businessreportable segment | revenue external | 2023-10-01 → 2024-09-30 | ¥768m |
| Contracted Cell Manufacturing Businessreportable segment | segment assets | at 2024-09-30 | ¥667m |
| Contracted Cell Manufacturing Businessreportable segment | segment profit | 2023-10-01 → 2024-09-30 | −¥374m |
| —segment total | capex | 2023-10-01 → 2024-09-30 | ¥44m |
| —segment total | depreciation | 2023-10-01 → 2024-09-30 | ¥97m |
| —segment total | revenue | 2023-10-01 → 2024-09-30 | ¥769m |
| —segment total | revenue external | 2023-10-01 → 2024-09-30 | ¥769m |
| —segment total | segment assets | at 2024-09-30 | ¥783m |
| —segment total | segment profit | 2023-10-01 → 2024-09-30 | −¥808m |
| Reconciling Itemsreconciling | capex | 2022-10-01 → 2023-09-30 | ¥6m |
| Reconciling Itemsreconciling | depreciation | 2022-10-01 → 2023-09-30 | ¥19m |
| Reconciling Itemsreconciling | segment assets | at 2023-09-30 | ¥4.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-10-01 → 2023-09-30 | −¥583m |
| Cellular And Tissue Based Product Businessreportable segment | capex | 2022-10-01 → 2023-09-30 | ¥25m |
| Cellular And Tissue Based Product Businessreportable segment | depreciation | 2022-10-01 → 2023-09-30 | ¥28m |
| Cellular And Tissue Based Product Businessreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥467,000 |
| Cellular And Tissue Based Product Businessreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥467,000 |
| Cellular And Tissue Based Product Businessreportable segment | segment assets | at 2023-09-30 | ¥169m |
| Cellular And Tissue Based Product Businessreportable segment | segment profit | 2022-10-01 → 2023-09-30 | −¥496m |
| Contracted Cell Manufacturing Businessreportable segment | capex | 2022-10-01 → 2023-09-30 | ¥30m |
| Contracted Cell Manufacturing Businessreportable segment | depreciation | 2022-10-01 → 2023-09-30 | ¥55m |
| Contracted Cell Manufacturing Businessreportable segment | revenue | 2022-10-01 → 2023-09-30 | ¥661m |
| Contracted Cell Manufacturing Businessreportable segment | revenue external | 2022-10-01 → 2023-09-30 | ¥661m |
| Contracted Cell Manufacturing Businessreportable segment | segment assets | at 2023-09-30 | ¥668m |
| Contracted Cell Manufacturing Businessreportable segment | segment profit | 2022-10-01 → 2023-09-30 | −¥346m |
| —segment total | capex | 2022-10-01 → 2023-09-30 | ¥55m |
| —segment total | depreciation | 2022-10-01 → 2023-09-30 | ¥84m |
| —segment total | revenue | 2022-10-01 → 2023-09-30 | ¥662m |
| —segment total | revenue external | 2022-10-01 → 2023-09-30 | ¥662m |
| —segment total | segment assets | at 2023-09-30 | ¥837m |
| —segment total | segment profit | 2022-10-01 → 2023-09-30 | −¥842m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 982
| Item | Context | Value | Unit |
|---|---|---|---|
| Targets description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 70.0 | |
| Performance description of metrics related to policy on development of human resources and internal environment and targets and performance using such metrics | CurrentYearInstant_Row1Member | 75.8 | |
| Research and development expenses research and development activities | CurrentYearDuration | 452775000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember | 78072000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 374702000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 46446000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05351-000ContractedCellManufacturingBusinessReportableSegmentsMember | 23014000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E05351-000CellularAndTissueBasedProductBusinessReportableSegmentsMember | 20997000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 264515306 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 264515306 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 264515306 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 264515306 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 2 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 28 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 160 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 31 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 142 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 52506 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 52869 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 32113 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 188896 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 66756 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 11608 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 14529 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 2331011 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 2644913 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 24006 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.0121 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0714 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.0252 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.0043 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0054 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.8813 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 7834922 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.0296 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 6902600 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0260 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 3396693 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0128 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 2996100 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0113 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 1571263 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0059 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 1500000 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0056 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 1400000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |